Treatment-related toxicity using prostate-only versus prostate and pelvic lymph node intensity-modulated radiation therapy: a national population-based study
Authors
Parry, MGSujenthiran, A
Cowling, TE
Nossiter, J
Cathcart, P
Clarke, Noel W
Payne, H
van der Meulen, J
Aggarwal, A
Affiliation
London School of Hygiene and Tropical Medicine, London, United KingdomIssue Date
2019
Metadata
Show full item recordAbstract
PURPOSE: There is a debate about the effectiveness and toxicity of pelvic lymph node (PLN) irradiation for the treatment of men with high-risk prostate cancer. This study compared the toxicity of intensity-modulated radiation therapy (IMRT) to the prostate and the pelvic lymph nodes (PPLN-IMRT) with prostate-only IMRT (PO-IMRT). MATERIALS AND METHODS: Patients with high-risk localized or locally advanced prostate cancer treated with IMRT in the English National Health Service between 2010 and 2013 were identified by using data from the Cancer Registry, the National Radiotherapy Dataset, and Hospital Episode Statistics, an administrative database of all hospital admissions. Follow-up was available up to December 31, 2015. Validated indicators were used to identify patients with severe toxicity according to the presence of both a procedure code and diagnostic code in patient Hospital Episode Statistics records. A competing risks regression analysis, with adjustment for patient and tumor characteristics, estimated subdistribution hazard ratios (sHRs) by comparing GI and genitourinary (GU) complications for PPLN-IMRT versus PO-IMRT. RESULTS: Three-year cumulative incidence in the PPLN-IMRT (n = 780) and PO-IMRT (n = 3,065) groups was 14% for both groups for GI toxicity, and 9% and 8% for GU toxicity, respectively. Patients receiving PPLN-IMRT and PO-IMRT had similar levels of severe GI (adjusted sHR, 1.00; 95% CI, 0.80 to 1.24; P = .97) and GU (adjusted sHR, 1.10; 95% CI, 0.83 to 1.46; P = .50) toxicity rates. CONCLUSION: Including PLNs in radiation fields for high-risk or locally advanced prostate cancer is not associated with increased GI or GU toxicity at 3 years. Additional follow-up is required to answer questions about its impact on late GU toxicity. Results from ongoing trials will provide insight into the anticancer effectiveness of PLN irradiation.Citation
Parry MG, Sujenthiran A, Cowling TE, Nossiter J, Cathcart P, Clarke NW, et al. Treatment-related toxicity using prostate-only versus prostate and pelvic lymph node intensity-modulated radiation therapy: a national population-based study. J Clin Oncol. 2019 Jun 4:JCO1802237.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.18.02237PubMed ID
31163009Additional Links
https://dx.doi.org/10.1200/JCO.18.02237Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.18.02237
Scopus Count
Collections
Related articles
- Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.
- Authors: Reis Ferreira M, Khan A, Thomas K, Truelove L, McNair H, Gao A, Parker CC, Huddart R, Bidmead M, Eeles R, Khoo V, van As NJ, Hansen VN, Dearnaley DP
- Issue date: 2017 Dec 1
- The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre Prospective Study.
- Authors: Tan MP, Harris V, Warren-Oseni K, McDonald F, McNair H, Taylor H, Hansen V, Sharabiani M, Thomas K, Jones K, Dearnaley D, Hafeez S, Huddart RA
- Issue date: 2020 Feb
- The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures.
- Authors: Yu T, Zhang Q, Zheng T, Shi H, Liu Y, Feng S, Hao M, Ye L, Wu X, Yang C
- Issue date: 2016
- Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer.
- Authors: Cobran EK, Chen RC, Overman R, Meyer AM, Kuo TM, O'Brien J, Sturmer T, Sheets NC, Goldin GH, Penn DC, Godley PA, Carpenter WR
- Issue date: 2016 Sep
- Intensifying the Hormonal and Radiation Treatment in Prostate Cancer Presenting With Bulky Pelvic Lymph Nodes: An Opportunity for a New Paradigm.
- Authors: Khan AH, Pervez N, Usmani MS, Almusalhi HS, Al Harthy M, Mula-Hussain L
- Issue date: 2024 Jan